Jefferies initiates coverage on PolyPeptide Group stock with Buy rating

Jefferies has initiated coverage on PolyPeptide Group AG (SIX:PPGN) with a Buy rating and a price target of CHF38.70. The firm views the Swiss-listed peptide CDMO as undervalued, noting it trades at a discount that implies growth materially below its own mid-term guidance, presenting compelling upside potential should the company deliver on its targets.

Analysis

Jefferies has initiated coverage on PolyPeptide Group AG (PPGN) with a 'Buy' rating and a price target of CHF 38.70, signaling a bullish outlook for the Swiss-listed pharmaceutical manufacturer. The core of Jefferies' thesis is a significant valuation disconnect, asserting that the market currently undervalues the company. The firm's analysis indicates that PolyPeptide, a quality peptide contract development and manufacturing organization (CDMO), trades at a discount that implies future growth materially below the company's own mid-term guidance for the 2024-2028 period. Jefferies highlights PPGN's strong technical capabilities and flexible manufacturing platform as key strengths. Consequently, the research firm projects "compelling upside potential" for the stock, contingent upon the company successfully delivering on its stated performance targets in the coming years.

Key Decisions for Investors

• Investors may consider the new 'Buy' rating and CHF 38.70 price target as a signal of significant potential upside, warranting a due diligence review of PolyPeptide's valuation relative to its peers.
• The investment thesis is heavily dependent on the company achieving its 2024-2028 guidance; therefore, investors should closely monitor future earnings reports and management commentary for execution against these targets.
• Given that the bullish case rests on the market's current pricing being overly pessimistic, investors should assess the risks that could prevent the company from meeting its growth guidance and justify the present discount.